JOHN E KAO, the Chief Executive Officer of $ALHC, sold 180,000 shares of the company on 10-10-2025 for an estimated $3,111,480. We received data on the trade from a recent SEC filing. This was a sale of approximately 6.2% of their shares of this class of stock. Following this trade, they now own 2,706,726 shares of this class of $ALHC stock.
$ALHC Insider Trading Activity
$ALHC insiders have traded $ALHC stock on the open market 41 times in the past 6 months. Of those trades, 0 have been purchases and 41 have been sales.
Here’s a breakdown of recent trading of $ALHC stock by insiders over the last 6 months:
- ATLANTIC, L.P. GENERAL has made 0 purchases and 3 sales selling 36,706,096 shares for an estimated $575,254,596.
- ATLANTIC (ALN HLTH), L.P. GENERAL has made 0 purchases and 3 sales selling 36,706,096 shares for an estimated $575,254,596.
- JOHN E KAO (Chief Executive Officer) has made 0 purchases and 9 sales selling 1,345,018 shares for an estimated $20,945,557.
- DAWN CHRISTINE MARONEY (President) has made 0 purchases and 8 sales selling 335,662 shares for an estimated $5,270,405.
- HYONG KIM (Chief Medical Officer) has made 0 purchases and 5 sales selling 147,034 shares for an estimated $2,431,524.
- ROBERT L. SCAVO (Chief Information Officer) has made 0 purchases and 4 sales selling 130,398 shares for an estimated $1,981,855.
- CHRISTOPHER J JOYCE (Chief Legal and Admin. Officer) has made 0 purchases and 4 sales selling 71,430 shares for an estimated $1,177,413.
- JOSEPH S KONOWIECKI has made 0 purchases and 3 sales selling 66,076 shares for an estimated $1,086,074.
- ANDREAS P. WAGNER (Chief Human Resources Officer) has made 0 purchases and 2 sales selling 31,431 shares for an estimated $494,209.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ALHC Hedge Fund Activity
We have seen 154 institutional investors add shares of $ALHC stock to their portfolio, and 85 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GENERAL ATLANTIC, L.P. removed 17,000,000 shares (-27.9%) from their portfolio in Q2 2025, for an estimated $238,000,000
- CITADEL ADVISORS LLC added 8,079,612 shares (+3307.7%) to their portfolio in Q2 2025, for an estimated $113,114,568
- MILLENNIUM MANAGEMENT LLC added 3,843,445 shares (+162.7%) to their portfolio in Q2 2025, for an estimated $53,808,230
- DURABLE CAPITAL PARTNERS LP removed 3,589,745 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $50,256,430
- WELLINGTON MANAGEMENT GROUP LLP removed 3,359,607 shares (-44.7%) from their portfolio in Q2 2025, for an estimated $47,034,498
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 3,253,607 shares (+35.8%) to their portfolio in Q2 2025, for an estimated $45,550,498
- INVESCO LTD. added 2,294,739 shares (+122.3%) to their portfolio in Q2 2025, for an estimated $32,126,346
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ALHC Analyst Ratings
Wall Street analysts have issued reports on $ALHC in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Goldman Sachs issued a "Buy" rating on 10/14/2025
To track analyst ratings and price targets for $ALHC, check out Quiver Quantitative's $ALHC forecast page.
$ALHC Price Targets
Multiple analysts have issued price targets for $ALHC recently. We have seen 4 analysts offer price targets for $ALHC in the last 6 months, with a median target of $19.0.
Here are some recent targets:
- Scott Fidel from Goldman Sachs set a target price of $21.0 on 10/14/2025
- Matthew Gillmor from Keybanc set a target price of $21.0 on 08/25/2025
- Andrew Mok from Barclays set a target price of $13.0 on 07/31/2025
- Kevin Caliendo from UBS set a target price of $17.0 on 05/02/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
